|
Mr. Ha-Ngoc is President and CEO of AVEO Pharmaceuticals Inc. AVEO formerly known as GenPath Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. From 1999 to 2002 he was co-founder President and CEO of deNovis Inc. an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999 Mr. Ha-Ngoc was Corporate Vice President of Strategic Development for Wyeth (formerly known as American Home Products Corporation) following Wyeth’s acquisition of Genetics Institute where Mr. Ha-Ngoc served as Executive Vice President with responsibility for Corporate Development Commercial Operations European and Japanese Operations. While at Genetics Institute he was also responsible for a major research and development program to develop bone morphogenetic protein (BMP) for the treatment of spinal fusion and long bone fractures and oversaw the commercial launch of BeneFIX (recombinant Factor IX) for the treatment of thrombocytopenia associated with chemotherapy. Prior to joining Genetics Institute in 1984 Mr. Ha-Ngoc held various marketing and business positions at Baxter Healthcare Inc. He received an MBA degree from INSEAD and a Master’s degree in pharmacy from the University of Paris France. Mr. Ha-Ngoc serves on the Board of Directors of Arqule Inc. and on the Boards of a number of academic and nonprofit organizations including the Harvard School of Dental Medicine the Tufts School of Medicine the Belmont Hill School the Boston Philharmonic Orchestra and the International Institute of Boston. | 